Disopiramida [Inn-Spanish]

Disopiramida [Inn-Spanish] Brand names, Disopiramida [Inn-Spanish] Analogs

Disopiramida [Inn-Spanish] Brand Names Mixture

No information avaliable

Disopiramida [Inn-Spanish] Chemical_Formula

C₂₁H₂₉N₃O

Disopiramida [Inn-Spanish] RX_link

http://www.rxlist.com/cgi/generic2/disopyr.htm

Disopiramida [Inn-Spanish] fda sheet

Disopiramida [Inn-Spanish] msds (material safety sheet)

Disopiramida [Inn-Spanish] Synthesis Reference

No information avaliable

Disopiramida [Inn-Spanish] Molecular Weight

339.475 g/mol

Disopiramida [Inn-Spanish] Melting Point

94.5-95 ^oC

Disopiramida [Inn-Spanish] H₂O Solubility

44.9 mg/L

Disopiramida [Inn-Spanish] State

Solid

Disopiramida [Inn-Spanish] LogP

3.972

Disopiramida [Inn-Spanish] Dosage Forms

Capsule; Tablet (extended-release)

Disopiramida [Inn-Spanish] Indication

For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias.

Disopiramida [Inn-Spanish] Pharmacology

Disopyramide is an antiarrhythmic drug indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia that are life-threatening. In man, Disopyramide at therapeutic plasma levels shortens the sinus node recovery time, lengthens the effective refractory period of the atrium, and has a minimal effect on the effective refractory period of the AV node. Little effect has been shown on AV-nodal and His-Purkinje conduction times or QRS duration. However, prolongation of conduction in accessory pathways occurs.

Disopiramida [Inn-Spanish] Absorption

Nearly complete

Disopiramida [Inn-Spanish] side effects and Toxicity

LD₅₀=580 mg/kg in rats

Disopiramida [Inn-Spanish] Patient Information